Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01175980 · OUTCOME

The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma · Source last updated 2020-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Genes sequenced in the WES assay.
Interval / dispersion
Not reported
Time frame
Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months

What was measured

Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets.

Analysis population: One of the cases that had FFPE blocks for the study.

Groups in this outcome

Treatment (Vorinostat)

Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Vorinostat)1

Reported measurements

Source class 1
Values in Genes sequenced in the WES assay. · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Vorinostat)21,522Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        21,522
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets.
groups
  1. description
    Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO
    id
    OG000
    title
    Treatment (Vorinostat)
param Type
NUMBER
population Description
One of the cases that had FFPE blocks for the study.
reporting Status
POSTED
time Frame
Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
title
The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample
type
OTHER_PRE_SPECIFIED
unit Of Measure
Genes sequenced in the WES assay.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice